These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 34985726)

  • 1. Predictive and prognostic significance of BRCAness in HER2-negative breast cancer.
    Sueta A; Yamamoto-Ibusuki M; Tomiguchi M; Fujiki Y; Goto-Yamaguchi L; Iwase H; Yamamoto Y
    Breast Cancer; 2022 Mar; 29(2):368-376. PubMed ID: 34985726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Tanino H; Kosaka Y; Nishimiya H; Tanaka Y; Minatani N; Kikuchi M; Shida A; Waraya M; Katoh H; Enomoto T; Sengoku N; Kajita S; Hoffman RM; Watanabe M
    PLoS One; 2016; 11(12):e0165721. PubMed ID: 27935989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of BRCAness Phenotype in Breast Tumors for the Appointment of Neoadjuvant Chemotherapy Based on Platinum and Taxanes.
    Tsyganov MM; Ibragimova MK; Garbukov EY; Bragina OD; Karchevskaya AA; Usynin EA; Litvyakov NV
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy.
    Akashi-Tanaka S; Watanabe C; Takamaru T; Kuwayama T; Ikeda M; Ohyama H; Mori M; Yoshida R; Hashimoto R; Terumasa S; Enokido K; Hirota Y; Okuyama H; Nakamura S
    Clin Breast Cancer; 2015 Feb; 15(1):80-5. PubMed ID: 25445419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCAness as a prognostic indicator in patients with early breast cancer.
    Liu L; Matsunaga Y; Tsurutani J; Akashi-Tanaka S; Masuda H; Ide Y; Hashimoto R; Inuzuka M; Watanabe C; Taruno K; Sawada T; Okuyama H; Ata A; Kuwayama T; Nakayama S; Tonouchi Y; Nakamura S
    Sci Rep; 2020 Dec; 10(1):21173. PubMed ID: 33273622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
    Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
    Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the BRCAness phenotype and its correlations with clinicopathological features in triple-negative breast cancers.
    Tian T; Shan L; Yang W; Zhou X; Shui R
    Hum Pathol; 2019 Feb; 84():231-238. PubMed ID: 30339969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
    Yang X; Rao J; Yang W; Shui R
    Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant Chemotherapy With Anthracycline-Based Regimen for BRCAness Tumors in Triple-Negative Breast Cancer.
    Teraoka S; Sato E; Narui K; Yamada A; Fujita T; Yamada K; Oba M; Ishikawa T
    J Surg Res; 2020 Jun; 250():143-147. PubMed ID: 32044511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer.
    Margeli M; Cirauqui B; Castella E; Tapia G; Costa C; Gimenez-Capitan A; Barnadas A; Sanchez Ronco M; Benlloch S; Taron M; Rosell R
    PLoS One; 2010 Mar; 5(3):e9499. PubMed ID: 20209131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study.
    Kosaka Y; Yamamoto Y; Tanino H; Nishimiya H; Yamamoto-Ibusuki M; Hirota Y; Iwase H; Nakamura S; Akashi-Tanaka S
    Diagnostics (Basel); 2020 Feb; 10(2):. PubMed ID: 32098267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness.
    Lips EH; Laddach N; Savola SP; Vollebergh MA; Oonk AM; Imholz AL; Wessels LF; Wesseling J; Nederlof PM; Rodenhuis S
    Breast Cancer Res; 2011 Oct; 13(5):R107. PubMed ID: 22032731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer.
    Mori H; Kubo M; Nishimura R; Osako T; Arima N; Okumura Y; Okido M; Yamada M; Kai M; Kishimoto J; Miyazaki T; Oda Y; Otsuka T; Nakamura M
    PLoS One; 2016; 11(12):e0167016. PubMed ID: 27977696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab.
    Fujita N; Enomoto Y; Inakami K; Yanagisawa T; Iguchi C; Aono T; Nomura T; Yamamoto H; Kasugai T; Shiba E
    Oncology; 2020; 98(1):35-41. PubMed ID: 31574500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers.
    Lips EH; Mulder L; Oonk A; van der Kolk LE; Hogervorst FB; Imholz AL; Wesseling J; Rodenhuis S; Nederlof PM
    Br J Cancer; 2013 May; 108(10):2172-7. PubMed ID: 23558900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of
    Akimoto E; Kadoya T; Kajitani K; Emi A; Shigematsu H; Ohara M; Masumoto N; Okada M
    Clin Breast Cancer; 2018 Feb; 18(1):45-52. PubMed ID: 28993056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
    Resende U; Cabello C; Ramalho SOB; Zeferino LC
    BMC Cancer; 2019 Jun; 19(1):601. PubMed ID: 31208353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
    Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
    Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Relationship of clinicopathological features and chemotherapeutic outcomes in women with BRCA1 and BRCA2 mutation-negative familial breast cancer].
    Zhang J; Sun J; Ouyang T; Li JF; Wang TF; Fan ZQ; Fan T; Lin BY; Xie YT
    Zhonghua Zhong Liu Za Zhi; 2016 Mar; 38(3):185-9. PubMed ID: 26988823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.